(Q38909847)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Synthesis and biological evaluation of geldanamycin analogs against human cancer cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Yan-ping Li

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jin-jing Chen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jia-jia Shen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jing Cui

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Lin-zhuan Wu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Zhuo-rong Li

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

14 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681003%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

773-782

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681003%20AND%20SRC:MED&resulttype=core&format=json

The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

The Hsp90 molecular chaperone: an open and shut case for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

HSP90 and the chaperoning of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Targeting the dynamic HSP90 complex in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Hsp90 molecular chaperone inhibitors: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Inhibition of HSP90 molecular chaperones: moving into the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Hsp90 inhibitors in breast cancer: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Geldanamycin biosynthesis and carbon magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Structure-based design of 7-carbamate analogs of geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Potent cytotoxic C-11 modified geldanamycin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Synthesis and biological activities of novel 17-aminogeldanamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

A novel class of geldanamycin derivatives as HCV replication inhibitors targeting on Hsp90: synthesis, structure-activity relationships and anti-HCV activity in GS4.3 replicon cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Poly(ADP-ribose) polymerase cleavage during apoptosis: when and where?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Hsp90 functions to balance the phosphorylation state of Akt during C2C12 myoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Phosphorylation accelerates geldanamycin-induced Akt degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9

Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2696-9